Native Kidney Denervation in Patients With End Stage Renal Disease

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00551304

Enrollment

Unknown

Registered

2007-10-30

Start date

2007-10-31

Completion date

Unknown

Last updated

2012-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease

Brief summary

To investigate the utility of renal denervation in the treatment of patients with End Stage Renal Disease (ESRD).

Interventions

DEVICEArdian Catheter

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adult \>= 18 years of age * end stage renal disease, undergoing concurrent dialysis treatment * poorly controlled blood pressure on at least 2 antihypertensive drugs * agrees to have the study procedure(s) performed and additional procedures and evaluations, including interventions and follow up visits * competent and willing to provide written, informed consent to participate in this clinical study.

Exclusion criteria

* renal arterial abnormalities * myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within six (6) months * hemodynamically significant valvular heart disease * implantable cardioverter defibrillator (ICD) or pacemaker * respiratory support. * pregnant, nursing or planning to be pregnant * other

Design outcomes

Primary

Measure	Time frame
To provide confirmation that renal denervation in ESRD patients is safe and feasible.	—

Secondary

Measure	Time frame
To provide evidence of denervation, indication of physiologic response, and assess device performance.	—

Countries

Australia, Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026